Noticias de SVRA_US

Mercado

Noticias del mercado

Últimas noticias sobre SVRA_US — 169 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SVRA_US ✕ 169 resultados
01/10/2026 SVRA_US — ad-hoc-news.de
Savara stock sits 26.39 percent below its 52-week high

Las acciones de Savara cuestan 4,59 euros el 1 de octubre de 2026 frente a 4,56 euros, más un 0,66 por ciento. Baja del segundo trimestre

26/09/2026 SVRA_US — Investing.com
Form 4 Savara Inc For: 25 September By Investing.com
25/09/2026 SVRA_US — Investing.com
Form 4 Savara Inc For: 25 September
25/09/2026 SVRA_US — Investing.com
Form 4 Savara Inc For: 25 September By Investing.com
25/09/2026 SVRA_US — Kalkine Media
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement
24/09/2026 SVRA_US — RTTNews
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?
23/09/2026 SVRA_US — Yahoo Finance
Savara Inc (YB4P.DU) Stock Price, News, Quote & History
18/09/2026 SVRA_US — DirectorsTalk Interviews
Savara, Inc. (SVRA) Stock Analysis: Exploring a Potential 101.80% Upside in Biotech Investment
16/09/2026 SVRA_US — careplusvn.com
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution
16/09/2026 SVRA_US — https://www.dars.gov.et/
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution - Full Year Guidance
16/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution - EBITDA Margin Trends
16/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution - Revenue Guidance Range
16/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Commercial Biotech Keeps Focus on Pipeline Execution
09/09/2026 SVRA_US — MarketBeat
Savara (SVRA) Institutional Ownership 2026

Which shareholders are buying/selling shares of Savara (NASDAQ:SVRA) stock? View SVRA institutional ownership (13F) transactions at MarketBeat.

08/09/2026 SVRA_US — careplusvn.com
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline Optimism - Earnings Power Value
08/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline Optimism - Earnings Momentum Score
08/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline Optimism - Revenue Miss Report
08/09/2026 SVRA_US — dars.gov.et
SVRA Q2 2026 Earnings: Wider-than-Expected Loss of $0.16 Per Share, Shares Rise 2.98% on Pipeline Optimism - Consensus Miss Rate
04/09/2026 SVRA_US — MyChesCo
Savara Builds Molgramostim Case With Long-Term Trial Data

YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) will present long-term efficacy and safety findings from its Phase 3 molgramostim trial Sept. 6 at the European Respiratory Society Congress in Barcelona, …

02/09/2026 SVRA_US — Moomoo
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)?

Página 2 de 9